Takeda Pharmaceutical Co Ltd - Q1 FY2023 Financial Summary
Business Context and Reporting Period
This Form 6-K filing summarizes the consolidated financial results for Takeda Pharmaceutical Company Limited for the three-month period ended June 30, 2022 (Q1 of Fiscal Year 2023). The report is prepared in accordance with International Financial Reporting Standards (IFRS) and was signed on July 28, 2022.
Key Financial Metrics
| Metric | Q1 FY2023 (Ended June 30, 2022) | Q1 FY2022 (Ended June 30, 2021) | YoY Change |
|---|---|---|---|
| Revenue | 972.5 billion JPY | 949.6 billion JPY | +2.4% |
| Operating Profit | 150.5 billion JPY | 248.6 billion JPY | -39.4% |
| Profit Before Tax | 155.5 billion JPY | 223.0 billion JPY | -30.3% |
| Net Profit | 105.0 billion JPY | 137.7 billion JPY | -23.7% |
| Basic EPS | 67.94 JPY | 87.96 JPY | -22.8% |
| Core Operating Profit | 319.1 billion JPY | 248.9 billion JPY | +28.2% |
| Core EPS | 145 JPY | 113 JPY | +28.3% |
| Total Assets | 14,065.4 billion JPY | 13,178.0 billion JPY (Mar 31, 2022) | N/A |
| Total Equity | 6,317.4 billion JPY | 5,683.5 billion JPY (Mar 31, 2022) | N/A |
| Cash & Equivalents | 646.0 billion JPY | 849.7 billion JPY (Mar 31, 2022) | -24.0% |
| Net Cash from Operating Activities | 84.2 billion JPY | 166.9 billion JPY | -49.5% |
Material Changes vs. Prior Period
- Revenue Growth: Reported revenue increased 2.4% year-over-year, driven by business momentum and favorable foreign exchange rates. However, on a Constant Exchange Rate (CER) basis, revenue declined 6.8%. The prior year period included a one-time 133.0 billion JPY gain from the sale of the diabetes portfolio in Japan, which is not present in the current period.
- Profitability Decline: Operating profit fell 39.4% and Net profit fell 23.7%. The decline in operating profit is largely attributed to the absence of the prior year's one-time divestiture gain, increased amortization and impairment losses (up 27.7%), and higher R&D expenses (up 17.2%).
- Core Performance: Excluding non-recurring items, Core Operating Profit grew 28.2% and Core EPS grew 28.3%, indicating strong underlying operational performance despite the reported GAAP decline.
- Therapeutic Area Performance:
- Growth: Gastroenterology (+28.4%), Rare Diseases (+16.8%), PDT Immunology (+32.3%), and Neuroscience (+25.6%) all showed significant growth.
- Decline: Oncology revenue decreased 3.2% due to rapid generic erosion of VELCADE in the U.S.
- Geographic Performance: Japan revenue dropped 45.7% due to the prior year's diabetes portfolio sale. The U.S. (+21.6%), Europe/Canada (+15.0%), and Latin America (+34.0%) showed strong growth.
Guidance, Outlook, and Risks
- Full Year Forecast (FY Ending March 31, 2023): Management has not revised its full-year forecast.
- Revenue: 3,690 billion JPY (+3.4% YoY).
- Operating Profit: 520 billion JPY (+12.8% YoY).
- Net Profit: 292 billion JPY (+26.9% YoY).
- Core Operating Profit: 1,100 billion JPY (+15.2% YoY).
- Management Guidance (Core Growth at CER):
- Core Revenue: Low-single-digit growth.
- Core Operating Profit: High-single-digit growth.
- Core EPS: High-single-digit growth.
- Risks and Contingencies:
- Ukraine/Russia Conflict: Takeda has suspended non-essential activities in Russia. Revenue from Russia/CIS represented only 1.8% of total revenue in Q1. Management expects no material financial impact in FY2023 but notes potential future adverse effects.
- COVID-19: The forecast includes approximately 50.0 billion JPY in revenue from COVID-19 vaccines (NUVAXOVID and SPIKEVAX). Management expects no material negative impact from the pandemic on FY2023 results.
- Foreign Exchange: The forecast assumes a weaker Yen (1 USD = 119 JPY) compared to the prior year (1 USD = 112 JPY).
Investor Verification Checklist
- One-Time Items: Verify the impact of the 133.0 billion JPY diabetes portfolio sale in the prior year to understand the true organic growth trajectory.
- Oncology Pipeline: Assess the long-term impact of VELCADE generic erosion and the performance of newer oncology products like ALUNBRIG and EXKIVITY.
- Core vs. Reported Metrics: Focus on Core Operating Profit and Core EPS as primary indicators of operational health, given the distortion in reported GAAP figures.
- Cash Flow: Review the significant decrease in operating cash flow (-49.5%) and the reduction in cash reserves to evaluate liquidity management.
- FX Sensitivity: Monitor the impact of the Yen's depreciation on future earnings, as it currently provides a tailwind to reported revenue but may affect cost structures.